AM-Pharma is focused on developing innovative treatments for severe medical conditions, particularly targeting cardiac surgery-associated renal damage (CSA-RD) and hypophosphatasia (HPP). Their proprietary compound, ilofotase alfa, is a recombinant alkaline phosphatase that has shown a strong safety profile and reno-protective effects in clinical trials involving over 1,000 subjects. The compound is being advanced into Phase 2 studies for CSA-RD, where it aims to prevent acute kidney injury (AKI) in patients undergoing cardiac surgery. Additionally, ilofotase alfa is being explored as a potential enzyme replacement therapy for HPP, a rare inherited disease characterized by low alkaline phosphatase levels, which is crucial for bone mineralization.

Ilofotase alfa operates by dephosphorylating and detoxifying damage-associated and pathogen-associated molecular patterns that contribute to inflammation and kidney injury. Research indicates that it can effectively reduce inflammation and improve kidney function, particularly in patients with AKI. The compound also addresses elevated biomarkers related to bone metabolism in HPP patients, potentially restoring skeletal integrity and alleviating associated symptoms. With orphan drug designations from the FDA and EMA, AM-Pharma is committed to providing treatment options for patients with these severe conditions, aiming to improve their quality of life and health outcomes.

Netherlands

AM-Pharma BV is a biopharmaceutical company developing recombinant Alkaline Phosphatase for clinical use.

AM Pharma

Company Details